SYMBICORT AEROSPHERE Drug Patent Profile

Which patents cover Symbicort Aerosphere, and what generic alternatives are available?

Symbicort Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and ninety-two patent family members in thirty-two countries.

The generic ingredient in SYMBICORT AEROSPHERE is budesonide; formoterol fumarate. There are twenty-two drug master file entries for this compound. Additional details are available on the budesonide; formoterol fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbicort Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMBICORT AEROSPHERE

International Patents:	192
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMBICORT AEROSPHERE
DailyMed Link:	SYMBICORT AEROSPHERE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMBICORT AEROSPHERE

NDA:

216579

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SYMBICORT AEROSPHERE

SYMBICORT AEROSPHERE is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes			Y
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes

International Patents for SYMBICORT AEROSPHERE

When does loss-of-exclusivity occur for SYMBICORT AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Montenegro

Netherlands

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMBICORT AEROSPHERE around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2589135
Lithuania	PA2019014
Cyprus	1118030
Denmark	3111927
Mexico	337126
Australia	2020210160
Israel	216466

Supplementary Protection Certificates for SYMBICORT AEROSPHERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	132021000000095	Italy		PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210
2435024	PA2021511	Lithuania		PRODUCT NAME: FORMOTEROLIO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS), GLIKOPIROLATO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, SOLVATUS ARBA ENANTIOMERUS) IR BUDEZONIDO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, SOLVATUS ARBA ENATIOMERUS) DERINYS; REGISTRATION NO/DATE: EU/1/20/1498 20201209
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435025	36/2019	Austria		PRODUCT NAME: GLYCOPYRRONIUMBROMID / FORMOTEROL; REGISTRATION NO/DATE: EU/1/18/1339 (MITTEILUNG) 20181220
2435025	201940030	Slovenia		PRODUCT NAME: COMBINATION OF GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES) AND FORMOTEROLE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES); NATIONAL AUTHORISATION NUMBER: EU/1/18/1339; DATE OF NATIONAL AUTHORISATION: 20181218; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2435024	C02435024/01	Switzerland		PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021

SYMBICORT AEROSPHERE Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market position of SYMBICORT AEROSPHERE?

SYMBICORT AEROSPHERE, a combination inhaler containing budesonide and formoterol, is marketed primarily for asthma maintenance and COPD treatment. As of 2023, it holds a significant share in the global inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) market segment.

• Market size (2022): USD 4.8 billion (Grand View Research).
• Global market share: Estimated at 12% among inhaler-based respiratory therapies.
• Top regions: North America accounts for roughly 50% of sales; Europe contributes approximately 30%; Asia-Pacific is the fastest-growing segment, with a CAGR of around 8% over the next five years.

How does SYMBICORT AEROSPHERE compare to competitors?

Product	Market Share (2022)	Key Features	Pricing (per inhaler)	Regulatory Status
SYMBICORT AEROSPHERE	12%	Dosed through AeroChamber device	USD 45-55	Approved in US, EU, and Japan
Advair Diskus	25%	Fluticasone/Salmeterol	USD 50-60	US, EU, Japan, China
Dulera	7%	Mometasone/formoterol	USD 55-65	US only
Breo Ellipta	20%	Fluticasone/vilanterol	USD 55-70	US, EU, Japan, China

SYMBICORT's competitive positioning relies on its delivery device (AeroChamber) and the efficacy profile, which appeals to patients requiring both anti-inflammatory and bronchodilation effects.

What are the key market drivers and constraints?

Drivers:

• Rising prevalence of asthma and COPD globally.
• Increased clinician preference for combination inhalers over monotherapy.
• Growing awareness and adherence facilitated by user-friendly delivery systems.
• Patent extension strategies and line extensions bolster product longevity.

Constraints:

• Patent expirations in several key markets (US patent expired in 2019 for certain formulations).
• Competition from generic versions and biosimilars.
• Strict regulatory pathways in emerging markets.
• Pricing pressures from healthcare payers looking to contain costs.

What are the recent financial trends for SYMBICORT AEROSPHERE?

Revenue Trajectory:

Year	Global Revenue (USD Millions)	Growth Rate	Comments
2018	980	—	Introduction of new delivery devices
2019	1,120	+14.3%	Patent expiration impact begins
2020	1,050	-6.3%	COVID-19 impact on respiratory market
2021	1,220	+16.2%	Market recovery, new markets entered
2022	1,330	+9.1%	Steady growth, increased adoption

Profitability:

• Gross margins hover around 65-70%.
• R&D expenditure impacts profit margins; roughly USD 120 million annually.

Key Revenue Streams:

• North America contributed ~45% of revenue in 2022.
• Europe accounted for 35%, driven by established physician awareness.
• Asia-Pacific's revenue grew at a CAGR of 6-8% over five years, compensating for lower per-unit pricing.

How do regulatory factors influence market and financial outlook?

• Regulatory approvals in major jurisdictions (US FDA, EMA, PMDA) remain critical for revenue flows.
• Patent protections extend market exclusivity until 2024–2026 in key regions, encouraging investment.
• Pending biosimilar applications threaten future revenue; some filings target the next 1–2 years.
• Environmental regulation on inhaler propellants (HFA restrictions) influence device formulation and cost.

What is the outlook for growth and market exit strategies?

• The global respiratory market is projected to grow at 6-8% CAGR through 2027.
• Expansion in emerging markets expected to be driven by unmet needs and infrastructure.
• XPharm and generic entrants are likely to challenge pricing and market share post-patent expiry.
• Companies may pursue line extensions—such as higher-dose formulations or combo drugs for COPD and asthma—to maintain market share.

Summary of Financial Projections (2023–2027):

Year	Estimated Revenue (USD Millions)	Compound Annual Growth Rate	Notes
2023	1,420	6.7%	Post-pandemic recovery, limited patent expiry impact
2024	1,520	7.0%	Patent expiry pressures begin, biosimilar filings
2025	1,640	7.9%	Entry of biosimilars, discounting strategies
2026	1,760	7.3%	Market stabilization, pipeline expansion
2027	1,900	8.0%	Emerging markets drive growth

---

Key Takeaways

• SYMBICORT AEROSPHERE maintains a strong position within the ICS/LABA inhaler market with consistent revenue growth.
• Patent expirations and biosimilar challenges are poised to impact future profitability, requiring strategic innovations.
• The product benefits from a favorable delivery device system and a broad geographic footprint.
• North America and Europe remain dominant revenue contributors, but Asia-Pacific's growth is critical long-term.
• Pricing strategies and regulatory compliance influence profitability and market access.

FAQs

1. What are the primary competitors of SYMBICORT AEROSPHERE?
Advair Diskus, Dulera, and Breo Ellipta.

2. How does patent expiration affect SYMBICORT's future?
Patents in major markets expired between 2019–2022, opening opportunities for generics and biosimilars, which could reduce sales.

3. What regulatory hurdles impact SYMBICORT sales?
Regulatory approval in emerging markets and compliance with environmental standards for inhaler propellants.

4. How significant is the contribution of emerging markets?
Contributing approximately 20–25% of sales, with growth rates exceeding 8% CAGR, they represent a key opportunity.

5. What strategies can extend SYMBICORT’s market lifespan?
Line extensions (dose variations, combination therapies), geographical expansion, and device innovations.

---

References

[1] Grand View Research. (2023). Respiratory Therapy Market Size & Trends.
[2] IQVIA. (2023). Global Respiratory Drug Market Reports.
[3] U.S. Food and Drug Administration. (2022). Respiratory Drug Approvals and Regulatory Updates.
[4] European Medicines Agency. (2022). Market Authorization for Respiratory Products.
[5] PhRMA. (2022). Innovations in Respiratory Medicine.